01.10.26 -- Outsourced Pharma Best Of December

By replacing trial-and-error with virtual simulations and predictive analytics, AI is giving even small biotechs the process development capabilities once reserved for Big Pharma—and slashing tech transfer timelines in the process.

This segment of the Outsourced Pharma Live event, “Small Molecule Outsourcing: Getting Timelines, Tech Transfer and Analytics Right,” outlines how sponsors can ensure that a CDMO’s quality systems and analytical outputs meet regulatory expectations by aligning early on target regions, building audit and qualification rights into contracts, executing robust quality agreements, monitoring QMS metrics, and overseeing third-party testing vendors.

When we began covering the nexus between GLP-1 drugs and CDMO capacity, there were two key questions: Could Big Pharma keep up with demand? Would the CDMO market also have capacity to serve the thousands of drug sponsors needing assistance with their non-GLP-1 programs? Those answers in 2025 tell us a lot about our industry heading into 2026.

Here are the factors that are driving blister to the forefront of pharmaceutical packaging, and at an even faster rate than its current growth.

Novel therapeutics are driving demand for alternative drug delivery methods. Explore the latest approaches and understand the formulation challenges and benefits for specific diseases.

We are beginning to see a rise in the interest of developing "orphan drugs," or pharmaceutical agents intended to treat rare diseases. Learn about the challenges and how to work through them.